With more than 11,000 deaths officially, the 2013-2016 Ebola epidemic has made 25 times more victims than the previous episodes observed for 40 years

Help the research

Donate !


Fruit bats are thought to be the natural hosts of the Ebola virus. Although the virus is no longer harmful for them, it is pathogenic in other wild animals from tropical rainforests, such as monkeys. Humans can be contaminated when handling these animals (butchering bushmeat, etc.). The virus then spreads among populations by human-to-human transmission.

In humans, the Ebola virus can be transmitted through direct contact with the blood or bodily fluids of sufferers, or through indirect contact with environments that have been contaminated by these fluids. The virus is not contagious during the incubation period. There is a moderate risk of infection in the first few hours after the initial symptoms appear, and a high risk once the disease has taken hold. Patients who have recovered from the disease are no longer infectious, but precautions are necessary, as men can continue to spread the virus through their semen up to several months after clinical recovery.

Epidemics are caused by secondary human-to-human transmission. They can be exacerbated if people caring for Ebola virus patients do not take sufficient precautions. Funerals and burial ceremonies in which friends and relatives come into direct contact with the bodies of the deceased also strongly increase the risk of spreading the virus.

The only way to curb epidemics and human-to-human transmission is to take appropriate precautions to avoid infection, including regular hand-washing, isolating patients and not allowing skin or mucosa to come into contact with infected fluids. Physical protection, such as gloves, masks, goggles, gowns and boots, is vital for these purposes. In recent years, two vaccines have been brought to market. One of these has been used to perform ring vaccination during outbreaks.


The Ebola virus disease is a severe acute viral illness. Early signs resemble flu-like symptoms and are hard to diagnose – they include the sudden onset of fever over 38°C, severe weakness, muscle pain, headache and sore throat. These symptoms are followed by vomiting, diarrhea, rash, impaired kidney and liver function and in some cases internal and external bleeding. The incubation period, in other words the time between infection and the first symptoms, varies from 2 to 21 days, but is usually between 5 and 12 days.

Laboratory testing is the only way of confirming the diagnosis. Samples are tested under the strictest possible containment conditions.


The Ebola virus was first observed in 1976, with two simultaneous outbreaks in Sudan (151 deaths) and the Democratic Republic of the Congo (280 deaths). It was named "Ebola" after a river that flows through the DRC.

The Ebola virus belongs to the family Filoviridae (filoviruses), which has five distinct species: Bundibugyo (BDBV), Zaire (EBOV), Reston (RESTV), Sudan (SUDV) and Taï Forest (TAFV). The Ebola Bundibugyo, Zaire and Sudan strains have caused around 20 outbreaks of the disease in Central Africa, in remote villages near forests. The main outbreaks were in:

  • 1995: 254 deaths in the Democratic Republic of the Congo,
  • 2000: 224 deaths in Uganda,
  • 2003: 128 deaths in the Congo,
  • 2007: 187 deaths in the Democratic Republic of the Congo.

Up to that point, the virus had claimed 1,590 victims.

In March 2014, a new outbreak of Zaire ebolavirus was identified in Guinea's forest region, spreading to neighboring countries Liberia and Sierra Leone and reaching urban areas. The virus then spread by air travel to Nigeria and by road to Senegal. By the time the World Health Organization (WHO) had announced the official end of the outbreak in June 2016, it had taken a serious toll, with at least 28,000 officially reported cases and over 11,000 deaths. This is the largest known outbreak to date. A further large-scale outbreak has since occurred in the Kivu region of the DRC and the virus has moreover reemerged in this country on three occasions. Finally, a rapidly contained outbreak took place in Guinea in 2021.


Sufferers of Ebola virus disease need intensive care to treat the symptoms (fever, pain and dehydration). In addition to the two available vaccines, monoclonal antibody-based treatments have proven relatively effective in humans and may therefore be used to supplement support treatments.


Virus Ebola vu en microscopie électronique à transmission - Institut Pasteur

Ebola 2013-2016: lessons learned and how to respond to new epidemics


At the Institut Pasteur

The Institut Pasteur and the Institut Pasteur International Network are assisting the international aid effort by offering diagnostic support and epidemiological surveillance.

  • The National Reference Center for Viral Hemorrhagic Fevers, Lyon

The Jean Mérieux-Inserm BSL-4 laboratory in Lyon has been closely involved since the start of the outbreak. The laboratory houses the French National Reference Center (CNR) for Viral Hemorrhagic Fevers, which operates under the Institut Pasteur's Biology of Viral Emerging Infections Unit, led by Sylvain Baize.

This team analyzed the first samples from Guinea during the 2013-2016 outbreak that hit West Africa, and made a positive diagnosis. Scientists also analyzed blood samples from patients and carried out tests to establish a detailed profile of the virus.

The team is on the front line of the fight against the Ebola virus. Besides analyzing samples in Lyon and monitoring suspected cases in France, it set up the Macenta diagnostic center in November 2014 and managed its patient screening operations during the outbreak occurring at that time. Alternating teams of volunteer scientists carried out work in the field. They were assigned from Sylvain Baize's team in Lyon and also various Institut Pasteur teams in Paris including the Laboratory for Urgent Response to Biological Threats (CIBU – see below).

In France, the National Reference Center for Viral Hemorrhagic Fevers, hosted by the Biology of Viral Emerging Infections Unit at the Institut Pasteur in Lyon, led by Sylvain Baize, has been tasked by the French Ministry of Health with contributing to diagnosis and epidemiological surveillance efforts for viral hemorrhagic fevers, in close collaboration with Santé publique France.

  • The Laboratory for Urgent Response to Biological Threats (CIBU)

In response to the Ebola epidemic that has been raging in West Africa since early 2014, the CIBU, led by Jean-Claude Manuguerra, has been involved in work to diagnose samples from Guinea, in collaboration with the CNR team in Lyon.


Statistics: WHO

June 2021

The Institut Pasteur teams working on the Ebola virus

National Reference Center for Viral Hemorrhagic Fevers, led by Sylvain Baize

Laboratory for Urgent Response to Biological Threats, led by Jean-Claude Manuguerra  

Viral genomics and vaccination Unit, led by Frédéric Tangy

Molecular virology and vaccinology Unit, led by Pierre Charneau

Functionnal genetics of infectious diseases Unit, led by Anavaj Sakuntabhai

Institut Pasteur de Dakar, led by Amadou Sall



Back to top